Pratik S. Multani, MD

home / authors / pratik-s-multani-md

Articles

Ibritumomab Tiuxetan Radioimmunotherapy Is Safe and Well Tolerated in Patients With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

T. E. Witzig;Leo I. Gordon, MD;G. A. Wiseman;S. Spies;C. Emmanouilides;Myron S. Czuczman, MD;I. W. Flinn;N. L. Barlett;J. L. Murray;B. Alkuzweny;Pratik S. Multani, MD;A. J. Grillo-Lopez, MD;Christine A. White, MD

March 1st 2001

Ibritumomab tiuxetan (Zevalin) consists of an anti-CD20 murine IgG1 kappa monoclonal antibody covalently bound to tiuxetan (MX-DTPA), which stably chelates yttrium-90 for therapy. Ibritumomab tiuxetan therapy involves pretreatment with

Final Results of a Randomized Controlled Study of the Ibritumomab Tiuxetan Radioimmunotherapy Regimen vs a Standard Course of Rituximab Immunotherapy for B-Cell Non-Hodgkin’s Lymphoma

T. E. Witzig;Christine A. White, MD;Leo I. Gordon, MD;J. L. Murray;G. A. Wiseman;C. Emmanouilides;Myron S. Czuczman, MD;D. Shen;Pratik S. Multani, MD;A. J. Grillo-Lopez, MD

March 1st 2001

Ibritumomab tiuxetan (Zevalin) is a murine anti-CD20 monoclonal antibody covalently bound to the chelator tiuxetan, which can securely chelate yttrium-90. We performed a randomized controlled trial

Clinical Status and Optimal Use of Rituximab for B-Cell Lymphomas

Michael L. Grossbard, MD;Pratik S. Multani, MD

December 1st 1998

Monoclonal antibodies (MoAbs) for cancer have been the subject of intense clinical investigation for nearly 2 decades.[1] Although the concept of MoAb therapy is simple, a host of unforeseen difficulties hindered the realization of clinical benefit from this therapeutic approach.